

Respiratory Syncytial Virus (RSV) A2 Matrix 2-1 (M2-1) Helper Plasmid, pA2-M2-1opt

Catalog No. NR-36464

For research use only. Not for human use.

Contributor:

BEI Resources

Manufacturer:

Martin L. Moore, Assistant Professor, Department of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA

Product Description:

NR-36464 is a component of a bacterial artificial chromosome (BAC)-based RSV rescue system that allows RSV infection to be monitored by fluorescence and is an important tool in RSV vaccine research and mutagenesis studies. Please refer to Appendix I for the manufacturer's RSV rescue protocol.

The M2-1 helper plasmid was constructed from codon-optimized RSV A2 M2-1 sequences. The codon-optimized cDNA sequences were synthesized and cloned into the pcDNA™3.1(+)⁴ mammalian expression plasmid (Life Technologies™ Invitrogen™).^{1,2} The plasmid was produced in *Escherichia coli*, strain 10-beta (a DH10B derivative, New England BioLabs®) and extracted using a Endo-Free Plasmid Maxi Kit (Qiagen).² The complete sequence for pA2-M2-1opt is reported in Appendix II.

Material Provided:

Each vial contains 0.5 µg of plasmid DNA in RNase/DNase-free 10 mM Tris-HCl, 1 mM EDTA buffer (pH 8). The concentration is shown on the Certificate of Analysis. The vial should be centrifuged prior to opening.

Packaging/Storage:

NR-36464 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen on dry ice and should be stored at -80°C or colder immediately upon arrival. Freeze-thaw cycles should be minimized.

Functional Activity:

Recombinant RSV was produced by co-transfection of BHK-21 clone BSR T7/5 cells³ with pSynkRSV-I19F, a BAC plasmid containing RSV A2-line19F antigenomic DNA and the gene for the far-red fluorescent protein monomeric Katushka 2 (mKate2) to enable detection of infection through fluorescence, (NR-36460) and four helper plasmids encoding sequence-optimized genes from RSV strain A2: large polymerase (L) (NR-36461), nucleoprotein (N) (NR-36462), phosphoprotein (P) (NR-36463) and matrix 2-1 protein (M2-1) (NR-36464). RSV rescue and infection could be detected by red fluorescent syncytia.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Respiratory Syncytial Virus (RSV) A2 Matrix 2-1 (M2-1) Helper Plasmid, pA2-M2-1opt, NR-36464."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmb15/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

- Hotard, A. L., et al. "A Stabilized Respiratory Syncytial Virus Reverse Genetics System Amendable to Recombination-Mediated Mutagenesis." Virology 434 (2012): 129-136. PubMed: 23062737.

2. M. L. Moore, Personnel Communication.
3. Buchholz, U. J., S. Finke and K. -K. Conzelmann. "Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA: BRSV NS2 Is Not Essential for Virus Replication in Tissue Culture, and Human RSV Leader Region Acts as a Functional BRSV Genome Promoter." J. Virol. 73 (1999): 251-259. PubMed: 9847328.

ATCC® is a trademark of the American Type Culture Collection.



Appendix I

Transfection Procedure for Virus Recovery of Recombinant Respiratory Syncytial Virus

Materials (Suggested suppliers and catalog numbers are indicated):

BHK-21 clone BSR T7/5 cell cultures or alternative cells [BHK21 cells (ATCC[®] CCL10[™]) transfected with phage T7 polymerase from Modified Vaccinia Ankara (MVA)] **Note:** This protocol is optimized for use with BHK-21 clone BSR T7/5 cells. Use of alternative cells may result in decreased recovery of RSV.

Opti-MEM (serum-free) (Gibco/Life Technologies catalog #11058-021)

GMEM [Glasgow's MEM (Gibco/Life Technologies catalog #11710-035)] + 3% FBS

MEM non-essential amino acids (NEAA) 100X solution (Gibco/Life Technologies catalog #11140-050)

G418 sulfate, 50 mg/mL solution (500X) (Agilent Technologies Genomics catalog # 200049)

Trypsin-EDTA (0.25%) (Gibco/Life Technologies catalog #25200-072)

Antibiotic-Antimycotic solution, penicillin/streptomycin/amphotericin (100X) (Corning cellgro[®] catalog #30-004-CI) or equivalent

Plasmid with RSV antigenome (NR-36460) each vial contains 0.5 µg in 5 µL total volume **Note:** This protocol requires 0.8 µg of pSynkRSV-I19F; thus 2 vials of NR-36460 are required per transfection.)

Helper Plasmids – (all codon optimized) each vial contains 0.5 µg in 5 µL total volume:

pA2-Lopt, L protein (NR-36461)

pA2-Nopt, N protein (NR-36462)

pA2-Popt, P protein (NR-36463)

pA2-M2-1opt, M2-1 protein (NR-36464)

Lipofectamine 2000 transfection reagent (Gibco/Life Technologies catalog #11668-019)

Phosphate buffered saline pH 7.2 (Gibco/Life Technologies catalog #20012027)

6-well tissue culture plates

25 cm² tissue culture flasks

Shaker/rocker plate

Tissue culture humidified incubator with 3% to 5% CO₂

Assorted sterile pipettes and tips

Procedure:

Note: This protocol assumes the user is familiar with cell culture techniques and transfection procedures.

1. Initial cell culture:
 - a. For routine sub-passage of BSR T7/5 cells, prepare new 25 cm² cultures at a ratio of one donor culture to three new cultures, based on surface area of the culture flasks (1:3 passage ratio). Use GMEM with 3% FBS + 1X NEAA + 1X antibiotics as growth medium, 5 mL per flask. When maintaining donor cultures, add 1X G418 to the growth medium every other passage.
 - b. For transfections, sub-pass BSR T7/5 cells from “donor” cultures into 6 well plates so they will be 100% confluent at time of transfection. Use one 25 cm² culture to prepare one 6 well plate (1:2.5 passage ratio).
2. Prepare 6 well plates for transfection from 25 cm² donor cultures. Determine how many plates will be required and use the corresponding number of flasks. Aspirate the growth medium from the flasks, and then add 0.25 mL of warm trypsin-EDTA per 25 cm² flask. Rock flasks to distribute the trypsin-EDTA and incubate at 37°C for 5 to 10 minutes. When cells start to dislodge from the flask, add 12 mL of GMEM with 3% FBS to each flask and use a pipet to suspend the cells in this growth medium. Add 2 mL of the cell suspension to each well in the 6 well plates. Incubate the plates at 37°C in the tissue culture incubator until the cell sheets are confluent and ready for transfection.
3. Prepare the reagents for the transfection procedure. Transfection will be done using Lipofectamine 2000 as the transfection reagent. Additionally, it is important to include control transfections (Lipofectamine only/wild type virus for mutants etc.)
 - a. Use a 3:1 ratio of Lipofectamine (µL) to plasmid/helper plasmid (µg). Dilute each component with Opti-MEM to make 100 µL of each. After dilution, allow each dilution to sit at room temperature for 5 minutes.
 - b. Use the following amounts of each component per transfection:

i.	RSV antigenome (NR-36460)	0.8 µg (8 µL of 0.1 µg/µL) + 92 µL Opti-MEM
		(2 vials of NR-36460 are required per transfection.)
ii.	pA2-Lopt, L protein (NR-36461)	0.2 µg (2 µL of 0.1 µg/µL) + 98 µL Opti-MEM
iii.	pA2-Nopt, N protein (NR-36462)	0.4 µg (4 µL of 0.1 µg/µL) + 96 µL Opti-MEM
iv.	pA2-Popt, P protein (NR-36463)	0.4 µg (4 µL of 0.1 µg/µL) + 96 µL Opti-MEM
v.	pA2-M2-1opt, M2-1 protein (NR-36464)	0.4 µg (4 µL of 0.1 µg/µL) + 96 µL Opti-MEM

vi. Lipofectamine 2000

6.6 μ L + 93.4 μ L Opti-MEM

Note: For multiple transfections increase the above quantities proportionally.

- c. After allowing the diluted components to sit at room temperature for 5 minutes, combine all six components in one vial, mix gently and incubate the transfection mixture at room temperature for 20 minutes.
 - d. Transfection mixtures should be 600 μ L total (Opti-MEM, Lipofectin, and DNA)
 - e. Aspirate the media from the BSR T7/5 cell culture plate, wash cells twice with 1 mL warm Opti-MEM for each wash, and aspirate the final wash.
 - f. Add 600 μ L transfection mixture to each well and incubate the plate 2 hours at room temperature on a shaker/rocker plate set at low speed.
 - g. After 2 hours, add an additional 600 μ L warm Opti-MEM per well and place plate in a 37°C tissue culture incubator overnight (8-12 hours).
4. After incubation, aspirate and discard the transfection mixture from the wells, wash each well once with 1 mL warm sterile PBS, aspirate the PBS and replace with 2 mL of warm GMEM with 3% FBS per well. Continue incubating at 37°C in the tissue culture incubator overnight.
 5. Day 2 post transfection, sub-pass the cells into 25 cm² flasks using the trypsin-EDTA procedure described above. Pass at a 1:3 surface area ratio unless cell morphology appears weak, in which case the ratio should be decreased accordingly up to an even 1:1 ratio. (Note: surface area of each well in the 6 well plate is 10 cm²). Cells should remain in GMEM with 3% FBS throughout the rest of recovery.
 6. Monitor flasks for cytopathic effect (CPE) and sub-pass at 1:3 ratio into new 25 cm² flasks as needed (approximately every 48 hours). CPE shows first as mini-syncytia and then grows into rounded up clumps of cells.
 7. When CPE is evident throughout the flask, scrape the cells into the growth media and aliquot into cryovials. Freeze at -80°C or colder.

Appendix 2: pA2-M2-1opt Sequence

1 GACGGATCGGGAGATCTCCCGATCCCCTATGGTGCACCTCTCAGTACAATCTGCTCTGATG 60
 CTGCCTAGCCCTCTAGAGGGGCTAGGGGATACCACGTGAGAGTCATGTTAGACGAGACTAC

61 CCGCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCG 120
 GGCATATCAATTCCGGTCATAGACGAGGGACGAACACACAACCTCCAGCGACTCATCACGC

121 CGAGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGC 180
 GCTCGTTTTAAATTTCGATGTTGTTCCGTTCCGAACCTGGCTGTTAACGTACTTCTTAGACG

181 TTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATT 240
 AATCCCAATCCGCAAAACGCGACGAAGCGCTACATGCCCGGTCTATATGCGCAACTGTAA

241 GATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTTCATTAGTTCATAGCCCATATA 300
 CTAATAACTGATCAATAATTATCATTAGTTAATGCCCCAGTAATCAAGTATCGGGTATAT

301 TGGAGTTCGCGGTTACATAAATTACGGTAAATGGCCCCGCTGGCTGACCGCCCAACGACC 360
 ACCTCAAGGCGCAATGTATTGAATGCCATTTACGGGGCGGACCGACTGGCGGGTTGCTGG

361 CCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCC 420
 GGGCGGGTAACTGCAGTTATTACTGCATACAAGGGTATCATTGCGGTTATCCCTGAAAGG

421 ATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGT 480
 TAACTGCAGTTACCCACCTCATAAATGCCATTTGACGGGTGAACCGTCATGTAGTTCACA

481 ATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCCGCTGGCATT 540
 TAGTATACGGTTCATGCGGGGGATAAATGCAGTTACTGCCATTTACGGGGCGGACCGTAA

541 ATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCA 600
 TACGGGTCATGTACTGGAATACCCTGAAAGGATGAACCGTCATGTAGATGCATAATCAGT

601 TCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTG 660
 AGCGATAATGGTACCACTACGCCAAAACCGTCATGTAGTTACCCGCACCTATCGCCAAAC

661 ACTCACGGGGATTTCCAAGTCTCCACCCATTGACGTCAATGGGAGTTTGTGTTTGGCACC 720
 TGAGTGCCCCATAAAGGTTTCAGAGGTGGGGTAACTGCAGTTACCCTCAAACAAAACCGTGG

721 AAAATCAACGGGACTTTCCAAAATGTCGTAACAACCTCCGCCCATTTGACGCAAATGGGCG 780
 TTTTAGTTGCCCTGAAAGGTTTTACAGCATTGTTGAGGCGGGGTAACCTGCGTTTACCCGC

781 GTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCA 840
 CATCCGCACATGCCACCCTCCAGATATATTCGTCTCGAGAGACCGATTGATCTCTTGGGT
 T7 promoter (863,881)
 |

841 CTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGC 900
 GACGAATGACCGAATAGCTTTAATTATGCTGAGTGATATCCCTCTGGGTTTCGACCGATCG
 KpnI RSV matrix 2-1 (929,1513)
 | |

901 GTTTAAACTTAAGCTTGGTACCGCCACCATGAGCCGGCGGAACCCCTGCAAGTTCGAGAT 960
 CAAATTTGAATTCGAACCATGGCGGTTGGTACTCGGCCGCTTGGGGACGTTCAAGCTCTA

961 CCGGGGCCACTGCCTGAACGGCAAGCGGTGCCACTTCAGCCACAACACTTTCGAGTGGCC 1020
GGCCCCGGTGACGGACTTGCCGTTGCCACGGTGAAGTCGGTGTGATGAAGCTCACCGG

1021 CCCTCACGCCCTGCTGGTGCGCCAGAACTTCATGCTGAACCGGATCCTGAAGTCCATGGA 1080
GGGAGTGCGGGACGACCACGCGGTCTTGAAGTACGACTTGGCCTAGGACTTCAGGTACCT

1081 CAAGAGCATCGACACCCTGAGCGAGATCAGCGGAGCTGCCGAGCTGGACCGGACCGAGGA 1140
GTTCTCGTAGCTGTGGGACTCGCTCTAGTCGCCTCGACGGCTCGACCTGGCCTGGCTCCT

1141 ATATGCCCTGGGCGTGGTGGGAGTGTGGAAAGCTACATCGGCAGCATCAACAACATCAC 1200
TATACGGGACCCGCACCACCCTCACGACCTTTCGATGTAGCCGTCGTAGTTGTTGTAGTG

1201 CAAGCAGAGCGCCTGCGTGGCCATGAGCAAGCTGCTGACCGAGCTGAACAGCGACGACAT 1260
GTTTCGTCTCGCGGACGCACCGGTACTCGTTCGACGACTGGCTCGACTTGTGCTGCTGTA

1261 CAAGAAGCTGCGGGACAACGAGGAACTGAACAGCCCCAAGATCCGGGTGTACAACACCGT 1320
GTTCTTCGACGCCCTGTTGCTCCTTGACTTGTGCGGGTCTTAGGCCACATGTTGTGGCA

1321 GATCAGCTACATCGAGAGCAACCGGAAGAACAACAAGCAGACCATCCATCTGCTGAAGCG 1380
CTAGTCGATGTAGCTCTCGTTGGCCTTCTTGTGTTTCGTCTGGTAGGTAGACGACTTCGC

1381 GCTGCCCGCCGACGTGCTGAAGAAAACCATCAAGAACACCCTGGACATCCACAAGTCCAT 1440
CGACGGGCGGCTGCACGACTTCTTTTGGTAGTTCTTGTGGGACCTGTAGGTGTTTCAGGTA

1441 CACCATCAACAACCCCAAAGAAAGCACCGTGTCCGACACCAACGACCAGCCAAGAACAA 1500
GTGGTAGTTGTTGGGGTTTCTTTTCGTGGCACAGGCTGTGGTTGCTGGTGCGGTTCTTGT
XhoI
|

1501 CGACACCACCTGACTCGAGTCTAGAGGGCCCGTTTAAACCCGCTGATCAGCCTCGACTGT 1560
GCTGTGGTGGACTGAGCTCAGATCTCCCGGGCAAATTTGGGCGACTAGTCGGAGCTGACA

1561 GCCTTCTAGTTGCCAGCCATCTGTTGTTTGGCCCTCCCCGTGCCTTCCTTGACCCTGGA 1620
CGGAAGATCAACGGTCGGTAGACAACAAACGGGGAGGGGGCACGGAAGGAAGTGGGACCT

1621 AGGTGCCACTCCCCTGTCCTTTTCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAG 1680
TCCACGGTGAGGGTGACAGGAAAGGATTATTTTACTCCTTTAACGTAGCGTAACAGACTC

1681 TAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGA 1740
ATCCACAGTAAGATAAGACCCCCACCCACCCCGTCCTGTGCTCCCCCTCCTAACCT

1741 AGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAAC 1800
TCTGTTATCGTCCGTACGACCCCTACGCCACCCGAGATACCGAAGACTCCGCCTTTCTTG
f1 origin(1844,2150)
|

1801 CAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGG 1860
GTCGACCCCGAGATCCCCATAGGGGTGCGCGGGACATCGCCGCGTAATTCGCGCCGCC

1861 TGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTT 1920
ACACCACCAATGCGCGTCGCACTGGCGATGTGAACGGTCGCGGGATCGCGGGCGAGGAAA

1921 CGCTTTCTTCCCTTCTTTCTCGCCACGTTGCGCGGCTTTCCCCGTCAAGCTCTAAATCG 1980
GCGAAAGAAGGGAAGGAAAGAGCGGTGCAAGCGGCCGAAAGGGGCAGTTCGAGATTTAGC

1981 GGGGCTCCCTTTAGGGTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAACTTGA 2040
 CCCCAGAGGAAATCCCAAGGCTAAATCACGAAATGCCGTGGAGCTGGGGTTTTTTGAACT

2041 TTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGAC 2100
 AATCCCCTACCAAGTGCATCACCCGGTAGCGGGACTATCTGCCAAAAAGCGGGAAACTG

2101 GTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCAAACTGGAACAACACTCAACCC 2160
 CAACCTCAGGTGCAAGAAATTATCACCTGAGAACAAGTTTTGACCTTGTGTGAGTTGGG

2161 TATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTTCGGCCTATTGGTTAAA 2220
 ATAGAGCCAGATAAGAAAATAAATATTCCTAAAACGGCTAAAGCCGGATAACCAATTT

2221 AAATGAGCTGATTTAACAAAAATTTAACCGGAATTAATTCTGTGGAATGTGTGTCAGTTA 2280
 TTTACTCGACTAAATTGTTTTTAAATTGCGCTTAATTAAGACACCTTACACACAGTCAAT
 SV40 promoter (2282,2603)

2281 GGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAAT 2340
 CCCACACCTTTTCAGGGGTCCGAGGGGTTCGTCCTTCATACGTTTCGTACGTAGAGTTA

2341 TAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGC 2400
 ATCAGTCGTTGGTCCACACCTTTTCAGGGGTCCGAGGGGTTCGTCCTTCATACGTTTCG
 SV40 origin (2449,2526)

2401 ATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCTAACTCCGCCCATCCCGCCCTA 2460
 TACGTAGAGTTAATCAGTCGTTGGTATCAGGGCGGGGATTGAGGCGGGTAGGGCGGGAT

2461 ACTCCGCCAGTTCCGCCATTCTCCGCCCATGGCTGACTAATTTTTTTTTATTTATGCA 2520
 TGAGGCGGGTCAAGGCGGGTAAGAGGCGGGTACCGACTGATTAAAAAAATAAATACGT

2521 GAGGCCGAGGCCGCTCTGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGGA 2580
 CTCCGGCTCCGGCGGAGACGGAGACTCGATAAGGTCTTCATCACTCCTCCGAAAAAACCT

2581 GGCCTAGGCTTTTGCAAAAAGCTCCCGGGAGCTTGTATATCCATTTTCGGATCTGATCAA 2640
 CCGGATCCGAAAACGTTTTTCGAGGGCCCTCGAACATATAGGTAAAAGCCTAGACTAGTT
 Neomycin^R (2665,3459)

2641 GAGACAGGATGAGGATCGTTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCG 2700
 CTCTGTCTACTCCTAGCAAAGCGTACTAACTTGTCTACCTAACGTGCGTCCAAGAGGC

2701 GCCGCTTGGGTGGAGAGGCTATTTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCT 2760
 CGGCGAACCACCTCTCCGATAAGCCGATACTGACCCGTGTTGTCTGTTAGCCGACGAGA

2761 GATGCCCGCGTGTTCGGCTGTTCAGCGCAGGGGCGCCGGTTCTTTTTGTCAAGACCGAC 2820
 CTACGGCGGCACAAGGCCGACAGTCGCGTCCCCGCGGGCCAAGAAAAACAGTTCTGGCTG

2821 CTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCACG 2880
 GACAGGCCACGGGACTTACTTGACGTCCTGCTCCGTCGCGCCGATAGCACCGACCGGTGC

2881 ACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTG 2940
 TGCCCCGAAGGAACGCGTCGACACGAGCTGCAACAGTGAAGTTTCGCCCTTCCCTGACCGAC

2941 CTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAA 3000
GATAACCCGCTTCACGGCCCCGTCTTAGAGGACAGTAGAGTGGAACGAGGACGGCTCTTT

3001 GTATCCATCATGGCTGATGCAATGCGGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCA 3060
CATAGGTAGTACCGACTACGTTACGCCGCCGACGTATGCGAACTAGGCCGATGGACGGGT

3061 TTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTIONCGGATGGAAGCCGGTCTT 3120
AAGCTGGTGGTTTCGCTTTGTAGCGTAGCTCGCTCGTGCATGAGCCTACCTTCGGCCAGAA

3121 GTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTTCGCC 3180
CAGCTAGTCTACTAGACCTGCTTCTCGTAGTCCCCGAGCGCGGTTCGGCTTGACAAGCGG

3181 AGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCTGACCCATGGCGATGCCTGC 3240
TCCGAGTTCGCGCGGTACGGGCTGCCGCTCTAGAGCAGCACTGGGTACCGCTACGGACG

3241 TTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTG 3300
AACGGCTTATAGTACCACCTTTTACCGGCGAAAAGACCTAAGTAGCTGACACCGGCCGAC

3301 GGTGTGGCGGACCCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTT 3360
CCACACCGCCTGGCGATAGTCTGTATCGCAACCGATGGGCACTATAACGACTTCTCGAA

3361 GGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCATTTCGCAG 3420
CCGCCGCTTACCCGACTGGCGAAGGAGCACGAAATGCCATAGCGGGGAGGGCTAAGCGTC

3421 CGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAA 3480
GCGTAGCGGAAGATAGCGGAAGAAGTCTCAAGAAGACTCGCCCTGAGACCCCAAGCTTT

3481 TGACCGACCAAGCGACGCCCAACCTGCCATCACGAGATTTTCGATTCCACCGCCGCTTCT 3540
ACTGGCTGGTTTCGCTGCGGGTTGGACGGTAGTGCTCTAAAGCTAAGGTGGCGGCGGAAGA

3541 ATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCG 3600
TACTTTCCAACCCGAAGCCTTAGCAAAAAGGCCCTGCGGCCGACCTACTAGGAGGTTCGCGC

3601 GGGATCTCATGCTGGAGTTCTTCGCCACCCCAACTTGTTTTATTGCAGCTTATAATGGTT 3660
CCCTAGAGTACGACCTCAAGAAGCGGGTGGGGTTGAACAAATAACGTCGAATATTACCAA

3661 ACAAATAAAGCAATAGCATCACAAATTTACAAATAAAGCATTTTTTTTCAGTGCATTCTA 3720
TGTTTTATTTCGTTATCGTAGTGTTTAAAGTGTTTATTTCGTAAAAAAGTGACGTAAGAT

3721 GTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGTATAACCGTCGACCTCTA 3780
CAACACCAACAGGTTTGTAGTAGTTACATAGAATAGTACAGACATATGGCAGCTGGAGAT

3781 GCTAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCA 3840
CGATCTCGAACCGCATTAGTACCAGTATCGACAAAGGACACACTTTAACAATAGGCGAGT
lac promoter (3852,3881)
|

3841 CAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCCTAATGAG 3900
GTTAAGGTGTGTTGTATGCTCGGCCTTCGTATTTACATTTTCGGACCCACGGATTACTC

3901 TGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGT 3960
ACTCGATTGAGTGTAATTAACGCAACGCGAGTGACGGGCGAAAGGTCAGCCCTTTGGACA

3961 CGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGC GTATTGGGC 4020
GCACGGTCGACGTAATTACTTAGCCGGTTGCGCGCCCCTCTCCGCCAAACGCATAACCCG

4021 GCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCCGGCTGCGGCGAGCGG 4080
CGAGAAGGCGAAGGAGCGAGTGACTGAGCGACGCGAGCCAGCAAGCCGACGCCGCTCGCC

4081 TATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAA 4140
ATAGTCGAGTGAGTTTCCGCCATTATGCCAATAGGTGTCTTAGTCCCCTATTGCGTCCTT
pBR322 origin (4190,4806)

4141 AGAACATGTGAGCAAAAAGGCCAGCAAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGG 4200
TCTTGTACTACTCGTTTTCCGGTCGTTTTCCGGTCCTTGGCATTTTTTCCGGCGCAACGACC

4201 CGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAATCGACGCTCAAGTCAGA 4260
GCAAAAAGGTATCCGAGGCGGGGGACTGCTCGTAGTGTTTTTTAGCTGCGAGTTCAGTCT

4261 GGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTTCCCCCTGGAAGCTCCCTCG 4320
CCACCGCTTTGGGCTGTCTGATATTTCTATGGTCCGCAAAGGGGGACCTTCGAGGGAGC

4321 TGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGG 4380
ACGCGAGAGGACAAGGCTGGGACGGCGAATGGCCTATGGACAGGCGGAAAGAGGGGAAGCC

4381 GAAGCGTGGCGCTTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTGTTT 4440
CTTTCGCACCGCGAAAGAGTATCGAGTGCGACATCCATAGAGTCAAGCCACATCCAGCAAG

4441 GCTCCAAGCTGGGCTGTGTGCACGAACCCCCGTTTCAGCCGACCGCTGCGCCTTATCCG 4500
CGAGGTTCGACCCGACACACGTGCTTGGGGGGCAAGTCGGGCTGGCGACGCGGAATAGGC

4501 GTAACATATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCA 4560
CATTGATAGCAGAACTCAGGTTGGGCCATTCTGTGCTGAATAGCGGTGACCGTTCGTCGGT

4561 CTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGT 4620
GACCATTGTCCTAATCGTCTCGCTCCATACATCCGCCACGATGTCTCAAGAACTTCACCA

4621 GGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAG 4680
CCGGATTGATGCCGATGTGATCTTCTTGTCTATAAACCATAGACGCGAGACGACTTCGGTC

4681 TTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCG 4740
AATGGAAGCCTTTTTCTCAACCATCGAGAACTAGGCCGTTTGTGGTGGCGACCATCGC

4741 GTTTTTTTGTGGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTT 4800
CAAAAAACAACGTTTCGTGCTCTAATGCGCGTCTTTTTTTTCTAGAGTTCTTCTAGGAA

4801 TGATCTTTTCTACGGGTCTGACGCTCAGTGAACGAAAACCTCACGTTAAGGGATTTTGG 4860
ACTAGAAAAGATGCCCCAGACTGCGAGTACCTTGCTTTTGAGTGCAATTCCTAAAACC

4861 TCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAATAAATGAAGTTTTA 4920
AGTACTCTAATAGTTTTTCCTAGAAGTGGATCTAGGAAAATTTAATTTTTACTTCAAAT
Ampicillin^R (4961,5821)

4921 AATCAATCTAAAGTATATATGAGTAACTTGGTCTGACAGTTACCAATGCTTAATCAGTG 4980
TTAGTTAGATTTTCATATATACTCATTTGAACCAGACTGTCAATGGTTACGAATTAGTCAC

4981 AGGCACCTATCTCAGCGATCTGTCTATTTTCGTTTCATCCATAGTTGCCTGACTCCCCGTCG 5040
TCCGTGGATAGAGTTCGCTAGACAGATAAAGCAAGTAGGTATCAACGGACTGAGGGGCAGC

5041 TG TAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGTGCAATGATACCGC 5100
ACATCTATTGATGCTATGCCCTCCCGAATGGTAGACCGGGGTCACGACGTTACTATGGCG

5101 GAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCG 5160
CTCTGGGTGCGAGTGGCCGAGGTCTAAATAGTCGTTATTTGGTTCGGTCGGCCTTCCCGGC

5161 AGCGCAGAAGTGGTCCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGG 5220
TCGCGTCTTACCAGGACGTTGAAATAGGCGGAGGTAGGTCAGATAATTAACAACGGCCC

5221 AAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAG 5280
TTCGATCTCATTTCATCAAGCGGTCAATTATCAAACGCGTTGCAACAACGGTAACGATGTC

5281 GCATCGTGGTGTACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCTCAACGAT 5340
CGTAGCACCACAGTGCAGCAGCAAACCATAACCGAAGTAAGTCGAGGCCAAGGGTTGCTA

5341 CAAGGCGAGTTACATGATCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTC 5400
GTTCCGCTCAATGTACTAGGGGGTACAACACGTTTTTTTCGCCAATCGAGGAAGCCAGGAG

5401 CGATCGTTGTCAGAAGTAAGTTGGCCGAGTGTATCACTCATGGTTATGGCAGCACTGC 5460
GCTAGCAACAGTCTTCATTCAACCGGCGTCACAATAGTGAGTACCAATACCGTCGTGACG

5461 ATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAA 5520
TATTAAGAGAATGACAGTACGGTAGGCATTCTACGAAAAGACACTGACCACTCATGAGTT

5521 CCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATAC 5580
GGTTCAGTAAGACTCTTATCACATACGCCGCTGGCTCAACGAGAACGGGCCGAGTTATG

5581 GGGATAATACCGCGCCACATAGCAGAACTTTAAAGTGCTCATCATTTGGAAAACGTTCTT 5640
CCCTATTATGGCGCGGTGTATCGTCTTGAAATTTTCACGAGTAGTAACCTTTTGAAGAA

5641 CGGGGCGAAAACCTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTC 5700
GCCCCGCTTTTGTAGAGTTCCTAGAATGGCGACAACCTTAGGTCAAGCTACATTGGGTGAG

5701 GTGCACCCAACCTGATCTTCAGCATCTTTTACTTTTACCAGCGTTTCTGGGTGAGCAAAAA 5760
CACGTGGGTTGACTAGAAGTCGTAGAAAATGAAAGTGGTCGCAAAGACCCACTCGTTTTT

5761 CAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCA 5820
GTCCTTCCGTTTTTACGGCGTTTTTTCCCTTATTCCCGCTGTGCCTTTACAACCTTATGAGT

5821 TACTCTTCCTTTTTCAATATTATTGAAGCATTATCAGGGTTATTGTCTCATGAGCGGAT 5880
ATGAGAAGGAAAAAGTTATAATAACTTCGTAAATAGTCCCAATAACAGAGTACTCGCCTA

5881 ACATATTTGAATGTATTTAGAAAAATAACAATAAGGGGTTCCGCGCACATTTCCCCGAA 5940
TGTATAAACTTACATAAATCTTTTTATTGTTTTATCCCCAAGGCGCGTGTAAGGGGCTT

5941 AAGTGCCACCTGACGTC 5957
TTCACGGTGGACTGCAG